Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery.
Clean Cells today announces the launch of operations in its new production suites, located in the new facility opened in January 2023.
Gene therapy is a rapidly growing area of medical science. But there is little in the way of safety testing the vectors used to deliver gene therapy.
Researchers at Gladstone Institutes have discovered that a rare genetic variant known as the "Christchurch mutation" can block detrimental effects of apolipoprotein E4, the best-established risk factor for the most common form of Alzheimer's disease.
A team of researchers from the Shenzhen Institute of Advanced Technology (SIAT) at the Chinese Academy of Sciences (CAS) and their collaborators have devised a gene therapy approach aimed at selectively manipulating the affected circuitry in Parkinson’s disease.
Severe Combined Immunodeficiencies (SCIDs) encompass a collection of serious primary immunodeficiency disorders primarily instigated by genetic mutations that disrupt the development of T-cells.
Severe Combined Immunodeficiencies (SCIDs) are a group of debilitating primary immunodeficiency disorders, primarily caused by genetic mutations that disrupt T-cell development.
A breakthrough by University of Zurich (UZH) researchers introduces a versatile technique for efficiently and safely delivering substantial genes, holding significant promise for therapeutic applications.
Researchers have developed a groundbreaking software tool known as DANGER analysis, offering a solution for safer and more precise genome editing.
Patients with X-linked severe combined immunodeficiency disorder (SCID-X1), often known as “bubble boy disease,” are born with a faulty gene that inhibits immune cells from being produced.
Researchers have used CRISPR gene editing, stem cells and human neurons to study the impact of a gene that is commonly mutated in autism.
Researchers from Rice University conducted tests to assess the safety and feasibility of gene delivery to various regions of the brain using a noninvasive technique based on ultrasound in rodents.
Broken String Biosciences today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures.
Unchained Labs, the life science tools company that’s all about getting biologics and gene therapy researchers the right tools for the job, announced today that life sciences ace, Scott Thomas, has joined the Company as Chief Commercial Officer.
The University of Michigan Department of Neurosurgery and Rogel Cancer Center study demonstrates enticing early results that a therapy merging cell-killing and immune-stimulating drugs is effective and safe in prolonging survival for patients with gliomas, an extremely aggressive form of brain cancer.
Researchers at Cincinnati Children’s Hospital reveal how damage to the cell’s energy factory causes muscle wasting. Closing a pore in the mitochondrial membrane in gene-edited mice prevents disease progression.
Waters Corporation introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors.
A new study from the University of Minnesota is the first to show that gene therapy can mend neural connections in people with Hurler syndrome, a rare hereditary brain condition.
A single injection of a novel CRISPR gene-editing treatment safely and efficiently removes SIV – a virus related to the AIDS-causing agent HIV – from the genomes of non-human primates, scientists at the Lewis Katz School of Medicine at Temple University now report.
Researchers at the University of Bristol have made a remarkable step forward in finding a potential cure for a type of childhood kidney disease.
Cytomos, an Edinburgh-based life science company that has developed a proprietary new approach to analysing cells, has secured £4 million to scale up market-testing of its technology platform Cytomos Dielectric Spectroscopy (CDS).